1.88
-0.03(-1.57%)
Currency In USD
| Previous Close | 1.91 |
| Open | 1.91 |
| Day High | 2 |
| Day Low | 1.86 |
| 52-Week High | 75 |
| 52-Week Low | 1.42 |
| Volume | 334,605 |
| Average Volume | 233,394 |
| Market Cap | 3.49M |
| PE | -0.16 |
| EPS | -12.12 |
| Moving Average 50 Days | 4.52 |
| Moving Average 200 Days | 12.52 |
| Change | -0.03 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $1.88 as of September 12, 2025 at a share price of $1.88. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $7.46 as of September 12, 2025 at a share price of $1.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
GlobeNewswire Inc.
Aug 13, 2025 8:05 PM GMT
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stag
BioVie Inc. Announces Closing of $12 Million Public Offering
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and
BioVie Inc. Announces Pricing of $12 Million Public Offering
GlobeNewswire Inc.
Aug 08, 2025 12:43 AM GMT
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and